Navigation Links
Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months
Date:4/14/2008

the preferred partner to continue development, commercialize and market the drug. Isis will transition development responsibility for mipomersen to Genzyme over the next year. In addition to the up-front payment ($150 million for Isis stock at $30 per share and $175 million mipomersen license fee), Isis also has the opportunity to receive from Genzyme up to $825 million in development and regulatory milestone payments plus up to $750 million in commercial milestone payments. Genzyme and Isis will share mipomersen profits. The profit share begins with a 70/30 Genzyme/Isis split and increases linearly to 50/50 when revenue reaches $2 billion.

Mipomersen is a second-generation antisense drug that reduces the production of apoB-100, a protein critical to the synthesis and transport of "bad" cholesterol. Cholesterol can be carried in the bloodstream in a variety of forms, with high-density lipoprotein, or HDL-cholesterol, being the good form, and low-density lipoproteins, or LDL-cholesterol, and very low-density lipoproteins, or VLDL-cholesterol, being bad forms directly involved in heart disease. Collectively lowering LDL-cholesterol, VLDL-cholesterol, and other bad forms of cholesterol are a key component in the prevention and management of cardiovascular disease.

Currently in Phase 3 development, mipomersen has been shown in Phase 2 trials to reduce cholesterol and other atherogenic lipids more than 40 percent beyond reductions achieved with standard lipid-lowering drugs, enabling more patients to achieve LDL-cholesterol targets. These trials have shown that treatment with mipomersen is well-tolerated, and that mipomersen has an attractive safety profile, and works equally well in the presence and absence of other lipid-lowering therapies including statins. A weekly injectable therapeutic, mipomersen is being developed primarily for patients at high cardiovascular risk who are unable to achieve target cholesterol levels with statins alone or who are into
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. VIA Pharmaceuticals Announces Updated DSMB Safety Results for VIA-2291 Ongoing Phase 2 Clinical Program
2. Clinical Update - Debio 0614 (Istaroxime) in Acute Heart Failure
3. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
4. Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update
5. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
6. Anti-Cancer Drug CYT997 Update
7. Access Pharmaceuticals to Conduct Conference Call to Update Financial Community
8. Oncology Drug Development Update - Molecular Profiling Redefines the Nature of Malignancy and Increases the Adoption of Targeted Therapeutics
9. Indevus Pharmaceuticals Provides Update on PRO 2000 Program
10. Clinical Update - Decapeptyl(R)/Trelstar(R) 6-Month Formulation in Advanced Prostate Cancer
11. Update on Progression of Phosphagenics and Nestle Nutritions Phospha E(R) Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Aug. 27, 2014 /PRNewswire-iReach/ -- In a new, ... the gap between the electronic medical record (EMR) ... readers can experience, first-hand, how seamless integration makes ... Photo - http://photos.prnewswire.com/prnh/20140827/140443 ... to imaging from within the patient record was ...
(Date:8/27/2014)... Columbia and MENLO PARK, Calif. ... Inc. , (OTCQB: DMPI), developer of advanced cancer ... at the 16th Annual Rodman & Renshaw Global Investment ... LLC. The presentation will take place Tuesday, September 9th at ... floor) at the New York Palace Hotel in ...
(Date:8/27/2014)... , Aug. 27, 2014 About 8 million ... due to buildup of fatty plaque in the arteries, ... aging patient population and in incidences of diabetes and ... its Lower Extremity Arterial RevascularizatioN (LEARN) meeting, ... Endovascular specialists and interested residents and fellows will be ...
Breaking Medicine Technology:DICOM Grid Launches Interactive Guide to Demonstrate Image-Enabling the EMR 2DelMar Pharmaceuticals To Present At The 16th Annual Rodman & Renshaw Global Investment Conference 2DelMar Pharmaceuticals To Present At The 16th Annual Rodman & Renshaw Global Investment Conference 3DelMar Pharmaceuticals To Present At The 16th Annual Rodman & Renshaw Global Investment Conference 4LEARN to Treat Peripheral Arterial Disease Patients 2LEARN to Treat Peripheral Arterial Disease Patients 3
(Date:8/27/2014)... 27, 2014 The American ... for the management and treatment of pulmonary arterial ... Arterial Hypertension in Adults: CHEST Guideline, in the ... for clinicians, and provide the latest and most ... Pulmonary Hypertension Association (PHA) – the country’s ...
(Date:8/27/2014)... 2014 The Latinos In Action Festival ... 7th at the Florida State Fair Grounds from 9am ... art and cultures from around the world. Latinos in ... Go Smart Mobile and Univision Mobile, a service provided ... an estimate of 4,000 people from different backgrounds, cultures ...
(Date:8/27/2014)... New Jersey’s own Morgan Hoffmann turned in ... during The Barclays – and thanks to finishing high ... four rounds, stepped his way into raising another $7,500 ... of New Jersey (Horizon BCBNSNJ) Walking Challenge. , Last ... before family and friends at the Paramus course, to ...
(Date:8/27/2014)... Seventy-three members of the founding class of the ... their careers as healthcare professionals at a traditional White ... four-year PharmD program traditionally receive white coats?a symbol of ... profession as colleagues dedicated to patient care. At the ... in Claremont, Calif., KGI President Sheldon Schuster welcomed the ...
(Date:8/27/2014)... of hormone therapy has spawned a prevalent but preventable ... hot flashes, according to a study by a Yale ... the study published in the Aug. 27 online issue ... that moderate to severe hot flashes also called ... women. Women with VMS experience more than feeling hot; ...
Breaking Medicine News(10 mins):Health News:Pulmonary Hypertension Association Endorses CHEST Guidelines for Treatment of Pulmonary Arterial Hypertension in Adults 2Health News:Marc Anthony to Perform at "Nieves Productions" Latinos in Action Festival 2Health News:Morgan Hoffmann, PGA TOUR Pro & Wyckoff Native, golfs and walks his way to top 10 finish at The Barclays while raising additional $7,500 for charity 2Health News:Founding Class of the KGI School of Pharmacy Formally Welcomed into the Profession at a Traditional White Coat Ceremony 2Health News:The high cost of hot flashes: Millions in lost wages preventable 2
... , WASHINGTON, July 22 The ... in the new book, Rethinking Responsibility: Reflections on Sex ... Teen and Unplanned Pregnancy, a nonprofit, nonpartisan organization, the volume includes ... , , , ...
... NEW YORK and SAN FRANCISCO, July 22 WeissComm ... Weiss , who was recently named an "Emerging Power Player" by ... the inaugural CLIO Healthcare Awards . The awards honor creative ... , About the CLIO Healthcare Awards and Entry ...
... HOUSTON, July 22 Service Corporation International (NYSE: SCI ) ... the second quarter 2009 on Wednesday, August 5, 2009, after the market ... Thursday, August 6, 2009. Details of the conference call are as ... Service Corporation International Second Quarter 2009 Earnings Conference Call , ...
... Proteus syndrome is a complex disorder associated with ... and unregulated adipose tissue. The overgrowth seen in ... Patients with Proteus syndrome require repeated treatment for ... period. Aggressive treatment may cause severe functional and ...
... , BINGHAM FARMS, Mich., July 22 ... as the new Director of Strategic Partnerships. Terrisca comes to ... Lives Save Dollars (SLSD) initiative where she served most recently as ... with key regional, state, national and international organizations to advance the ...
... , , , ... Board: ACCP) announced today that Jeffrey B. Davis, President & CEO, ... the LifeTech Capital Group on Thursday, July 30, 2009 at 10:45 am EDT. ... Astoria Boca Beach Club in Boca Raton, Florida. , , ...
Cached Medicine News:Health News:National Leaders Examine Sex and Responsibility in New Book 2Health News:National Leaders Examine Sex and Responsibility in New Book 3Health News:WeissComm Group CEO Jim Weiss Appointed Founding Board Member and Judge of First-Ever CLIO Healthcare Awards 2Health News:WeissComm Group CEO Jim Weiss Appointed Founding Board Member and Judge of First-Ever CLIO Healthcare Awards 3Health News:Service Corporation International Announces Schedule For Its Second Quarter 2009 Earnings Release and Conference Call 2Health News:Terrisca Des Jardins, MHSA, joins my1HIE as Director of Strategic Partnerships 2Health News:Access Pharmaceuticals to Present at Jessup & Lamont 2009 Growth Stock Conference 2
The S7 Elite is the premium device in ResMeds award-winning S7 series. All S7 devices include an option of integrated humidification....
... The S8 Elite is the premium CPAP device ... generators. The S8 line of flow generators are ... first flow generators to include an option of ... to the device for simplicity and convenience. Premium ...
... freedom and flexibility with the integrated ... battery pack, the system will be ... Also includes an integrated heated humidifier. ... water for one nights use, and ...
... The GoodKnight 420 CPAP System is ... pressure (CPAP) device on the market. It ... patients preserve their lifestyles while complying with ... to 600 sessions of date/time usage data. ...
Medicine Products: